Factores de riesgo asociados a nefrotoxicidad por cisplatino en pacientes con cáncer.
Saved in:
| Title: | Factores de riesgo asociados a nefrotoxicidad por cisplatino en pacientes con cáncer. |
|---|---|
| Alternate Title: | Risk factors associated with cisplatin nephrotoxicity in cancer patients. |
| Authors: | Delia Maceda-Nazario, Nancy1,2, Zurita-Cruz, Jessie N.3 zuritajn@hotmail.com, del Carmen Zepeda-Martínez, Claudia1,2, Alejandra Alegría-Torres, Gabriela1,2, Betanzos-Cabrera, Yadira2,4 |
| Source: | Revista Mexicana de Pediatria. Nov/Dec2024, Vol. 91 Issue 6, p222-227. 6p. |
| Subjects: | PROXIMAL kidney tubules, DISEASE risk factors, MAGNESIUM sulfate, MANN Whitney U Test, GLOMERULAR filtration rate |
| Abstract (English): | Introduction: cisplatin-associated nephrotoxicity is primarily related to the accumulation of metabolites in proximal renal tubule cells. Objective: to identify risk factors associated with nephrotoxicity in pediatric cancer patients who received cisplatin. Material and methods: retrospective cohort study. Patients with solid tumors treated between 2015 and 2021 who received cisplatin as part of their oncological treatment were included. All were followed until they completed the cisplatin regimen. Clinical and laboratory data were recorded. Magnesium sulfate use, nephrotoxic administration, cumulative cisplatin dose, and changes in renal function (creatinine and glomerular filtration rate [GFR]) were documented for each chemotherapy cycle. Nephrotoxicity was defined as an increase in serum creatinine > 0.5 mg/dL from baseline. Statistical analysis: comparisons between groups were made using the χ², Fisher’s exact, and Mann-Whitney U tests. Control of confounding variables was with Cox proportional hazards (HR). Results: a total of 101 patients were studied; the median age was 11 years, and 62.4% were men. Median serum creatinine increased from 0.47 mg/dL to 0.72 mg/dL at the end of surveillance, while GFR decreased from 120 to 82 mL/min/1.73 m². Nephrotoxicity was present in 23.8% of patients, and tubulopathy in 14.8%. Magnesium sulfate administration (HR 0.233; 95% CI 0.926-0.587; p = 0.002) and higher serum phosphorus levels before the start of chemotherapy (HR 0.529; 95% CI 0.315-0.888; p = 0.016) were determined as protectors for this complication. Conclusions: in pediatric cancer patients, the incidence of cisplatin-induced nephrotoxicity is approximately 20%. The administration of magnesium sulfate and higher serum phosphorus concentrations are protective factors for the development of nephrotoxicity. [ABSTRACT FROM AUTHOR] |
| Abstract (Spanish): | Introducción: la nefrotoxicidad asociada al uso de cisplatino está relacionada principalmente con la acumulación de metabolitos en las células del túbulo renal proximal. Objetivo: identificar factores de riesgo asociados a nefrotoxicidad en pacientes pediátricos con cáncer que reciben cisplatino. Material y métodos: estudio de cohorte retrospectivo. Se incluyeron pacientes con tumores sólidos, atendidos entre 2015 y 2021, que recibieron cisplatino como parte del tratamiento oncológico. A todos se siguieron hasta completar el esquema de cisplatino. Se registraron datos clínicos y de laboratorio. De cada ciclo de quimioterapia se documentó el uso de sulfato de magnesio, administración de nefrotóxicos, dosis acumulada de cisplatino y cambios en la función renal (creatinina y tasa de filtrado glomerular [TFG]). La nefrotoxicidad se definió como el aumento de la creatinina sérica > 0.5 mg/dL, respecto al valor inicial. Análisis estadístico: la comparación entre grupos fue con las pruebas χ², exacta de Fisher y U Mann-Whitney. El control de las variables de confusión fue con riesgos proporcionales de Cox. Resultados: se estudiaron 101 pacientes; la mediana de edad fue de 11 años y el 62.4% fueron varones. La mediana de creatinina sérica aumentó al final de la vigilancia de 0.47 mg/ dL a 0.72 mg/dL, mientras la TFG descendió de 120 a 82 mL/min/1.73 m². El 23.8% desarrolló nefrotoxicidad, y 14.8% tubulopatía. La administración de sulfato de magnesio (HR 0.233; IC95% 0.926-0.587; p = 0.002) y mayores niveles de fósforo sérico antes del inicio de la quimioterapia (HR 0.529; IC95% 0.315-0.888; p = 0.016) resultaron como protectores de esta complicación. Conclusiones: en pacientes pediátricos con cáncer, la frecuencia de nefrotoxicidad por cisplatino es de alrededor del 20%. La administración de sulfato de magnesio y las mayores concentraciones séricas de fósforo son factores protectores para el desarrollo de nefrotoxicidad. [ABSTRACT FROM AUTHOR] |
| Copyright of Revista Mexicana de Pediatria is the property of Sociedad Mexicana de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | MedicLatina |
| FullText | Links: – Type: pdflink Text: Availability: 0 |
|---|---|
| Header | DbId: lth DbLabel: MedicLatina An: 186657356 AccessLevel: 6 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Factores de riesgo asociados a nefrotoxicidad por cisplatino en pacientes con cáncer. – Name: TitleAlt Label: Alternate Title Group: TiAlt Data: Risk factors associated with cisplatin nephrotoxicity in cancer patients. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AR" term="%22Delia+Maceda-Nazario%2C+Nancy%22">Delia Maceda-Nazario, Nancy</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Zurita-Cruz%2C+Jessie+N%2E%22">Zurita-Cruz, Jessie N.</searchLink><relatesTo>3</relatesTo><i> zuritajn@hotmail.com</i><br /><searchLink fieldCode="AR" term="%22del+Carmen+Zepeda-Martínez%2C+Claudia%22">del Carmen Zepeda-Martínez, Claudia</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Alejandra+Alegría-Torres%2C+Gabriela%22">Alejandra Alegría-Torres, Gabriela</searchLink><relatesTo>1,2</relatesTo><br /><searchLink fieldCode="AR" term="%22Betanzos-Cabrera%2C+Yadira%22">Betanzos-Cabrera, Yadira</searchLink><relatesTo>2,4</relatesTo> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22Revista+Mexicana+de+Pediatria%22">Revista Mexicana de Pediatria</searchLink>. Nov/Dec2024, Vol. 91 Issue 6, p222-227. 6p. – Name: Subject Label: Subjects Group: Su Data: <searchLink fieldCode="DE" term="%22PROXIMAL+kidney+tubules%22">PROXIMAL kidney tubules</searchLink><br /><searchLink fieldCode="DE" term="%22DISEASE+risk+factors%22">DISEASE risk factors</searchLink><br /><searchLink fieldCode="DE" term="%22MAGNESIUM+sulfate%22">MAGNESIUM sulfate</searchLink><br /><searchLink fieldCode="DE" term="%22MANN+Whitney+U+Test%22">MANN Whitney U Test</searchLink><br /><searchLink fieldCode="DE" term="%22GLOMERULAR+filtration+rate%22">GLOMERULAR filtration rate</searchLink> – Name: Abstract Label: Abstract (English) Group: Ab Data: Introduction: cisplatin-associated nephrotoxicity is primarily related to the accumulation of metabolites in proximal renal tubule cells. Objective: to identify risk factors associated with nephrotoxicity in pediatric cancer patients who received cisplatin. Material and methods: retrospective cohort study. Patients with solid tumors treated between 2015 and 2021 who received cisplatin as part of their oncological treatment were included. All were followed until they completed the cisplatin regimen. Clinical and laboratory data were recorded. Magnesium sulfate use, nephrotoxic administration, cumulative cisplatin dose, and changes in renal function (creatinine and glomerular filtration rate [GFR]) were documented for each chemotherapy cycle. Nephrotoxicity was defined as an increase in serum creatinine > 0.5 mg/dL from baseline. Statistical analysis: comparisons between groups were made using the χ², Fisher’s exact, and Mann-Whitney U tests. Control of confounding variables was with Cox proportional hazards (HR). Results: a total of 101 patients were studied; the median age was 11 years, and 62.4% were men. Median serum creatinine increased from 0.47 mg/dL to 0.72 mg/dL at the end of surveillance, while GFR decreased from 120 to 82 mL/min/1.73 m². Nephrotoxicity was present in 23.8% of patients, and tubulopathy in 14.8%. Magnesium sulfate administration (HR 0.233; 95% CI 0.926-0.587; p = 0.002) and higher serum phosphorus levels before the start of chemotherapy (HR 0.529; 95% CI 0.315-0.888; p = 0.016) were determined as protectors for this complication. Conclusions: in pediatric cancer patients, the incidence of cisplatin-induced nephrotoxicity is approximately 20%. The administration of magnesium sulfate and higher serum phosphorus concentrations are protective factors for the development of nephrotoxicity. [ABSTRACT FROM AUTHOR] – Name: Abstract Label: Abstract (Spanish) Group: Ab Data: Introducción: la nefrotoxicidad asociada al uso de cisplatino está relacionada principalmente con la acumulación de metabolitos en las células del túbulo renal proximal. Objetivo: identificar factores de riesgo asociados a nefrotoxicidad en pacientes pediátricos con cáncer que reciben cisplatino. Material y métodos: estudio de cohorte retrospectivo. Se incluyeron pacientes con tumores sólidos, atendidos entre 2015 y 2021, que recibieron cisplatino como parte del tratamiento oncológico. A todos se siguieron hasta completar el esquema de cisplatino. Se registraron datos clínicos y de laboratorio. De cada ciclo de quimioterapia se documentó el uso de sulfato de magnesio, administración de nefrotóxicos, dosis acumulada de cisplatino y cambios en la función renal (creatinina y tasa de filtrado glomerular [TFG]). La nefrotoxicidad se definió como el aumento de la creatinina sérica > 0.5 mg/dL, respecto al valor inicial. Análisis estadístico: la comparación entre grupos fue con las pruebas χ², exacta de Fisher y U Mann-Whitney. El control de las variables de confusión fue con riesgos proporcionales de Cox. Resultados: se estudiaron 101 pacientes; la mediana de edad fue de 11 años y el 62.4% fueron varones. La mediana de creatinina sérica aumentó al final de la vigilancia de 0.47 mg/ dL a 0.72 mg/dL, mientras la TFG descendió de 120 a 82 mL/min/1.73 m². El 23.8% desarrolló nefrotoxicidad, y 14.8% tubulopatía. La administración de sulfato de magnesio (HR 0.233; IC95% 0.926-0.587; p = 0.002) y mayores niveles de fósforo sérico antes del inicio de la quimioterapia (HR 0.529; IC95% 0.315-0.888; p = 0.016) resultaron como protectores de esta complicación. Conclusiones: en pacientes pediátricos con cáncer, la frecuencia de nefrotoxicidad por cisplatino es de alrededor del 20%. La administración de sulfato de magnesio y las mayores concentraciones séricas de fósforo son factores protectores para el desarrollo de nefrotoxicidad. [ABSTRACT FROM AUTHOR] – Name: AbstractSuppliedCopyright Label: Group: Ab Data: <i>Copyright of Revista Mexicana de Pediatria is the property of Sociedad Mexicana de Pediatria and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract.</i> (Copyright applies to all Abstracts.) |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=lth&AN=186657356 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.35366/120537 Languages: – Code: spa Text: Spanish PhysicalDescription: Pagination: PageCount: 6 StartPage: 222 Subjects: – SubjectFull: PROXIMAL kidney tubules Type: general – SubjectFull: DISEASE risk factors Type: general – SubjectFull: MAGNESIUM sulfate Type: general – SubjectFull: MANN Whitney U Test Type: general – SubjectFull: GLOMERULAR filtration rate Type: general Titles: – TitleFull: Factores de riesgo asociados a nefrotoxicidad por cisplatino en pacientes con cáncer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Delia Maceda-Nazario, Nancy – PersonEntity: Name: NameFull: Zurita-Cruz, Jessie N. – PersonEntity: Name: NameFull: del Carmen Zepeda-Martínez, Claudia – PersonEntity: Name: NameFull: Alejandra Alegría-Torres, Gabriela – PersonEntity: Name: NameFull: Betanzos-Cabrera, Yadira IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 11 Text: Nov/Dec2024 Type: published Y: 2024 Identifiers: – Type: issn-print Value: 00350052 Numbering: – Type: volume Value: 91 – Type: issue Value: 6 Titles: – TitleFull: Revista Mexicana de Pediatria Type: main |
| ResultId | 1 |
